[Radioimmunoimaging of malignant melanoma with In-111 labeled monoclonal antibody 96.5 and ZME-0.18].
In-111 labeled mouse antimelanoma monoclonal antibody (MoAb) type 96.5 and ZME-018 were examined in patients with malignant melanoma. These antibodies were supplied by Hybriteck Inc. MoAb was conjugated with DTPA first and then labeled with In-111. Radioimmunolocalization of an In-111-MoAb, type 96.5, was investigated in 23 patients with metastatic malignant melanoma. One of the 23 patients examined twice was found to be without any side effects. Seventeen out of these patients were examined with Ga-67 scintigraphy to evaluate clinical usefulness of radioimmunoimaging. Of a total of 58 metastases which had been diagnosed previously by conventional techniques, 45 were visualized by In-111-96.5 scans for an overall true positive image rate of 77.6%. But the imaging rate by Ga-67 scan was 67.4%. From examining for MoAb, ZME-018, in 15 patients, of a total of 43 metastases, 28 were detected by In-111-ZME-018 scan, with an imaging rate of 65.1%. But the imaging rate in Ga-67 scan was 43.2%. Clinical usefulness was recognized to be effective in radioimmunoimaging with MoAb, 111In-111-96.5 and In-111-ZME-018, for the diagnosis of malignant melanoma.
Ishii
K
K
Dept. of Radiology, Kitasato University School of Medicine.
Nishiyama
S
S
Oyamada
H
H
Endo
K
K
D000911:Antibodies, Monoclonal; D002951:Citrates; D019343:Citric Acid; D006801:Humans; D007205:Indium Radioisotopes; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000276:immunology / Q000556:secondary; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D002951:Citrates; D007205:Indium Radioisotopes; D019343:Citric Acid